TAM
CRSP icon

Tucker Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Tucker Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.9K Buy
+207
New +$12.4K ﹤0.01% 563
2025
Q1 		– Sell
-12
Closed -$472 – 430
2024
Q4 		$472 Buy
+12
New +$567 ﹤0.01% 1416
2024
Q2 		– Sell
-1,114
Closed -$75.9K – 1695
2024
Q1 		$75.9K Buy
+1,114
New +$79.7K 0.02% 339
2023
Q2 		– Sell
-207
Closed -$9.36K – 1195
2023
Q1 		$9.36K Buy
+207
New +$10.1K ﹤0.01% 566

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tucker Asset Management's CRSP Position: Q4 2025 in Review

Tucker Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q4 2025: 207 shares worth $10.9K. The stake represents ﹤0.01% of the portfolio and ranks #563 among its holdings. This is a return to the name: Tucker Asset Management previously reported a position in CRSP as recently as Q4 2024.

Tucker Asset Management first reported a position in CRSP in Q1 2023 and has held it in 4 quarters since. The position peaked at $75.9K in Q1 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Tucker Asset Management held 207 shares of CRISPR Therapeutics worth $10.9K as of Q4 2025.
  • CRISPR Therapeutics was a new Tucker Asset Management position in Q4 2025.
  • CRISPR Therapeutics made up ﹤0.01% of Tucker Asset Management's portfolio in Q4 2025, its #563 holding.
  • Tucker Asset Management first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Tucker Asset Management's CRISPR Therapeutics position peaked at $75.9K in Q1 2024.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Tucker Asset Management's 13F filing for Q4 2025, filed 5 Feb 2026.